On January 8, 2026, HATAPHAR officially received the “Top 10 Most Reputable Pharmaceutical Manufacturing Companies in Vietnam 2025” award. Additionally, Hataphar was honored as one of the VNR500 (Top 500 Largest Enterprises in Vietnam) for 2025.
This marks the 9th year that Hataphar has been featured in this prestigious ranking. This impressive achievement serves as a significant milestone, reaffirming the brand’s sustainable growth and leading position in the Vietnamese pharmaceutical market.
A Rigorous and Independent Evaluation
The “Top 10 Most Reputable Pharmaceutical Manufacturing Companies in Vietnam 2025” ranking is an annual, independent study conducted by Vietnam Report (Vietnam Report Joint Stock Company) and published by VietnamNet. The ranking aims to identify and honor pharmaceutical enterprises that not only operate efficiently but also make meaningful contributions to the industry while building strong public trust.
To ensure objectivity and scientific accuracy, Vietnam Report evaluates companies based on three main criteria:
- Financial Capacity: Assessed through the most recent financial reports.
- Media Reputation: Evaluated using the Media Coding method.
- Stakeholder Trust: Based on extensive surveys with industry experts, pharmacists, and consumers nationwide.
This achievement is the “sweet fruit” of a long journey of relentless effort, especially significant as Hataphar reflects on its 60-year history of formation and development. It recognizes a sound business strategy that prioritizes product quality as a vital factor and adopts community health responsibility as the guiding principle for all actions.
This award serves as a powerful motivator, fueling strategic steps for the future. A key project for the company is the Hataphar High-Tech Pharmaceutical Manufacturing Plant in Hoa Lac, built according to JAPAN-GMP standards. This is a large-scale collaboration between Hataphar and its strategic partner, ASKA Pharmaceutical (Japan).
With a total Phase 1 investment exceeding 820 billion VND, the Hataphar high-tech plant is expected to become one of the most modern pharmaceutical production facilities in the region. Strong investment in advanced technology and high automation will allow Hataphar to enhance production capacity and optimize quality. This ensures that international-standard pharmaceutical products reach Vietnamese consumers at reasonable prices while confidently expanding into global markets.
Hataphar is taking decisive steps to elevate its brand comprehensively, aiming for all production lines to meet JAPAN-GMP or equivalent standards. With a solid foundation of 60 years of experience, three modern factories, and a dedicated team of over 1,000 employees, Hataphar is steering toward becoming a top-revenue enterprise in Vietnam by 2040 and a renowned pharmaceutical brand within Southeast Asia.
